"Metformin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
| Descriptor ID |
D008687
|
| MeSH Number(s) |
D02.078.370.141.450
|
| Concept/Terms |
Metformin- Metformin
- Dimethylbiguanidine
- Dimethylguanylguanidine
|
Below are MeSH descriptors whose meaning is more general than "Metformin".
Below are MeSH descriptors whose meaning is more specific than "Metformin".
This graph shows the total number of publications written about "Metformin" by people in this website by year, and whether "Metformin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2004 | 2 | 1 | 3 |
| 2006 | 1 | 0 | 1 |
| 2008 | 1 | 1 | 2 |
| 2010 | 2 | 0 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 0 | 2 | 2 |
| 2015 | 2 | 0 | 2 |
| 2016 | 2 | 0 | 2 |
| 2017 | 2 | 0 | 2 |
| 2019 | 2 | 1 | 3 |
| 2020 | 2 | 0 | 2 |
| 2022 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
| 2024 | 2 | 0 | 2 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Metformin" by people in Profiles.
-
Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes : A Randomized Clinical Trial. Ann Intern Med. 2026 Jul; 179(7):917-928.
-
Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial. BMJ. 2024 10 15; 387:e080122.
-
Favorable Antiviral Effect of Metformin on SARS-CoV-2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of COVID-19. Clin Infect Dis. 2024 08 16; 79(2):354-363.
-
Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. Lancet Infect Dis. 2023 10; 23(10):1119-1129.
-
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. N Engl J Med. 2022 08 18; 387(7):599-610.
-
Metformin in chronic kidney disease: a strong dose of caution. Kidney Int. 2020 11; 98(5):1101-1105.
-
Metformin Should Not Be Used to Treat Prediabetes. Diabetes Care. 2020 09; 43(9):1983-1987.
-
Randomized controlled trial comparing hydroxychloroquine with pioglitazone as third-line agents in type 2 diabetic patients failing metformin plus a sulfonylurea: A pilot study. J Diabetes. 2020 Jan; 12(1):91-94.
-
Antidiabetic Medications and Mortality Risk in Individuals With Pancreatic Cancer-Related Diabetes and Postpancreatitis Diabetes: A Nationwide Cohort Study. Diabetes Care. 2019 09; 42(9):1675-1683.
-
Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2019 04; 21(4):883-892.